Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-158 pembrolizumab biomarker study in advanced rare solid tumors
MOH_2022-07-25_011929Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in Nonhematologic neoplasms (2 cohorts), sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Jan 2016; status: recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2022-07-25_011929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-25_011929.